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Abstract
Liver transplantation is a high-risk surgery performed on a high-risk patient and is the 
only treatment for end-stage liver disease. Ever since the first successful liver transplant 
performed, patient survival increased due to improvement of surgical technique and 
anaesthetic management as well as the emergence of new generations of immunosup-
pressants. The pre-anaesthetic evaluation is mandatory and plays an important role in 
patient inclusion on the transplant list. Liver transplantation is performed under general 
anaesthesia, and the anaesthetic monitoring is very important for a successful liver trans-
plantation as it can expose problems before irreversible damage occurs. Haemodynamic 
instability is common during surgery, requiring complex invasive haemodynamic moni-
toring. Continuous assessment of the patient’s volemic status and the amount of perfused 
fluids represent the key to a successful liver transplantation. Inadequate fluid therapy can 
lead to pulmonary oedema, abnormal gas exchange, congestion, decrease in perfusion 
and oedema of the graft. Liver reperfusion takes place in the neohepatic phase and is the 
most unstable period during liver transplantation, representing a real challenge for the 
anaesthetist. It can have severe consequences due to a decrease in cardiovascular function 
with haemodynamic instability, abnormal acid base balance and metabolic abnormalities.
Keywords: liver transplant, cirrhotic cardiomyopathy, postreperfusion syndrome
1. Introduction
Liver transplantation is the only treatment for end-stage liver disease regardless of its aetiol-
ogy as well as for other categories of liver failure. The procedure is performed on a high-risk 
patient with impairment of cardiovascular, pulmonary, renal and coagulation systems. Due to 
increasingly good results, transplant candidates are older and frequently have co-morbidities.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Since the first transplant interventions in the 1960s, postintervention morbidity rate decreased 
and patient survival increased. This is due to the improvement of surgical technique and 
anaesthetic management as well as the emergence of new generations of immunosuppres-
sants. Medical care of pre-transplant patients has also experienced a favourable evolution.
The outcome of patients undergoing liver transplantation depends on the perioperative man-
agement. Dedicated and specialized teams for liver transplantation have a major role on the 
outcome of these patients.
2. Preoperative assessment
Liver transplantation is a high-risk surgery performed on a high-risk patient, the cirrhotic 
patient with end-stage liver disease. The pre-anaesthetic evaluation is mandatory and plays 
an important role in accepting the inclusion of the patient on the transplant list. Today, 
patients eligible for transplant are older and often associate co-morbidities.
2.1. Cardiac evaluation
2.1.1. Coronary artery disease (CAD)
The cirrhotic patient has long been considered to be protected from coronary artery disease 
(CAD) due to his/her haemodynamic profile associated to a low serum cholesterol level. 
However, recent studies show that CAD has the same prevalence in this group compared 
to the general population. Patients frequently associate risk factors for CAD such as obesity, 
diabetes and hypertension.
The incidence of CAD does not seem to be influenced by the aetiology of cirrhosis except for 
non-alcoholic steatohepatitis (NASH), in which case it is twice as high, NASH associating with 
the metabolic syndrome [1]. The importance of CAD detection is due to the haemodynamic high 
stress during liver transplant leading to exacerbation of the cardiac suffering during surgery 
or generating postoperative cardiac complications [2, 3]. Recognizing CAD is very important, 
but the best therapeutic approach in case of significant coronary stenosis is not well defined.
Coronary angioplasty may be recommended, but due to the need for heavy anti-aggregation, 
this may increase the risk of bleeding in the cirrhotic patient. When required, bare metal stents 
are preferred to pharmacologically active ones because of a shorter period of anti-aggregation. 
Surgical intervention for myocardial revascularization is not recommended due to a very high 
mortality risk in the cirrhotic patient [2, 4].
2.1.2. Cirrhotic cardiomyopathy
Cirrhotic patients have myocardial dysfunction secondary to hepatic impairment [5].
Regardless of the aetiology of cirrhosis, cardiomyopathy is characterized by
• increased cardiac output at baseline,
• impaired contractile reserve in response to stress; this is due to a lower density of beta adren-
ergic receptors as well as to the negative inotropic effect of excess nitric oxide production,
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• diastolic dysfunction; it is more pronounced in patients with ascites,
• electrophysiological alterations like prolongation of the QT interval [3, 6].
The prolonged QT interval is associated with the severity of liver disease and the degree of 
portal hypertension as well as mortality [2]. A QTc interval of >440 ms correlates with an 
increased risk of ventricular arrhythmias [7].
Both diastolic and systolic dysfunction can be causes of postoperative pulmonary oedema. 
Right heart dysfunction, when present, has a higher predictive value for postoperative car-
diac complications.
2.1.3. Other causes for cardiac impairment
Chronic consumption of ethanol may cause dilated cardiomyopathy; it is characterized by 
left ventricular dilatation with altered systolic function. In the initial stages of heart disease, 
abstinence from alcohol can significantly improve the symptoms.
In the case of haemochromatosis, excess iron will be deposited in the myocardium, leading to 
restrictive cardiomyopathy [2].
2.1.4. Steps of cardiac evaluation
Investigating a patient will begin with the existence of a history of heart disease as well as 
symptoms suggestive of cardiovascular events such as rhythm disorders or angina. Because 
of their low exercise capacity due to cirrhosis, the incidence of angina is low and frequently 
coronary heart disease can be underestimated.
The baseline assessment includes an electrocardiographic (ECG) recording at rest and an 
echocardiography.
The echocardiography evaluates the following [8]:
• measurements of cardiac chambers
• valvular characteristics and function
• evaluation of systolic function of the left ventricle (LV) expressed as ejection fraction; we must 
not forget that these values are obtained under the conditions of low blood pressure due to 
the vasodilatation of the cirrhotic patient, so they can underestimate the real ejection fraction
• evaluation of diastolic function of the left ventricle by measuring early and late diastolic ve-
locities through the mitral valve to determine the E/A ratio (ventricular filling phases = initial 
E vs. tardive A); E/A < 1 reflects a diastolic dysfunction; diastolic dysfunction is more pro-
nounced in patients with ascites [6]
If electrocardiogram and echocardiography are two mandatory pre-transplant investigations, 
the question is what other methods should be used in those patients who require additional 
methods.
According to AASLD (American Association for the Study of Liver Disease), AHA (American 
Heart Association) and ACCF (American College of Cardiology Foundation), additional 
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investigations should be undertaken for patients who have three or more associated risk fac-
tors of the following: diabetes, left ventricular hypertrophy, history of CAD, age > 60 years, 
smoking, hypertension, dyslipidaemia and obesity [4, 9].
Several types of investigations have been proposed:
• stress echocardiography using dobutamine, adenosine or dipyridamole,
• myocardial perfusion scintigraphy,
• computerized cardiac tomography which allows calculating the calcium score; this is a 
rapid and non-invasive way to measure calcium deposits in the coronary vessel wall as an 
expression of coronary stenosis; results are measured in Ca scores: a Ca of >100 score car-
ries a moderate risk of cardiac events and a score of >400 a high risk [10].
Valvular dysfunctions in the cirrhotic patient on the transplant list are poorly studied. The 
evaluation of such a patient should include the severity of the valve dysfunction, either steno-
sis or regurgitation, the degree of alteration of myocardial contractility and the clinical pres-
ence of signs of insufficient cardiac output. Several cases of simultaneous liver transplantation 
and aortic valve replacement for tight aortic stenosis were reported in the cirrhotic patient [6].
2.2. Pulmonary system
Chronic liver disease can affect both the pleural space and the pulmonary parenchyma. 
The two pulmonary conditions characteristic of the cirrhotic patient are hepatopulmonary 
syndrome and pulmonary hypertension. The two syndromes exclude each other, and their 
pathophysiology depends on predominant vasodilator or vasoconstrictor elements resulting 
from liver dysfunction.
Portopulmonary hypertension is a pulmonary hypertension syndrome with vascular obstruc-
tion, coexisting with portal hypertension. The portopulmonary syndrome has important hae-
modynamic consequences with minor changes in blood gases.
All patients proposed for transplantation should be screened for portopulmonary hyper-
tension as the postoperative evolution depends on it. It might be suspected in the case of a 
right branch block on ECG. Echocardiography can detect pulmonary hypertension and can 
evaluate it, but correct values are obtained by right heart catheterization. Depending on the 
mean pressure in the pulmonary artery (PAPm), hypertension is classified in mild (PAPm 
25–34 mmHg), moderate (PAPm 35–44 mmHg) and severe (PAPm >45 mmHg).
Severe pulmonary hypertension excludes the patient from liver transplantation; moderate 
form may benefit from vasodilator drug treatment in pre-transplant [4]. Decision to perform 
liver transplant in this case depends on the response to therapy and is taken by the transplant 
team on an individual basis.
Hepatopulmonary syndrome is characterized by hypoxemia secondary to intrapulmo-
nary shunt due to vascular dilation. In contrast with pulmonary hypertension that may be 
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aggravated by surgery for liver transplant, the hepatopulmonary syndrome’s evolution is 
extremely favourable post transplantation with net amelioration or even complete resolution.
The cirrhotic patient might develop pleural effusions. The hydrothorax appears most fre-
quently on the right side and generally accompanies ascites. It is due to an anatomical defect 
in the right hemidiaphragm. Sometimes, it might need drainage prior to surgery [11–13].
The cirrhotic patient may suffer from any other pulmonary disease not related to the chronic 
liver failure. Chronic obstructive pulmonary disease may be associated with cirrhosis, espe-
cially in smoker patients, resulting in obstructive respiratory insufficiency, which together 
with restrictive ascites dysfunction may greatly compromise respiratory function. Patients 
will be evaluated by a pneumologist for treatment and encouraged to quit smoking.
Since the necessary immunosuppression after transplantation may lead to reactivation of a 
dormant latent tuberculosis, it is mandatory to test transplant candidates for latent tubercu-
losis. This is done either with the tuberculin skin test or with the quantiferon TB test, a cell 
immune response assay using a Mycobacterium tuberculosis-like protein substrate.
Depending on the lung’s status, investigations will be limited to a chest X-ray or will go 
further to pulmonary ultrasound or computed tomography (CT) scan of the thorax [14, 15].
2.3. Evaluation of renal function
Renal dysfunction in the cirrhotic patient is due to a decreased blood volume due to vaso-
dilation, with a decrease in glomerular filtration. It may not be reflected correctly in serum 
creatinine levels; the end-stage liver disease patient often has a less muscle mass and a low 
creatinine production. Higher sensitivity tests are cystatin C or NGAL (neutrophil gelatinase-
associated lipocalin).
Two types of kidney dysfunction are related to cirrhosis: hepatorenal syndrome is type 1 with 
rapid deterioration in renal function (doubling serum creatinine or increasing it to >2.5 mg/dl 
in less than 2 weeks) and a type 2 with slower evolution.
The occurrence of renal dysfunction can be precipitated by haemorrhage and infection [4, 16]. 
Preoperative renal dysfunction increases the risk of adverse development of postoperative 
complications.
2.4. Coagulation status
Coagulation abnormalities are caused by reduced concentrations of vitamin K-dependent fac-
tors and an imbalance between procoagulant and anticoagulant factors. Standard coagulation 
tests do not reflect rebalanced haemostasis and must not be used to predict the risk of bleed-
ing. Procoagulant factors must not be administered unless signs of bleeding are present [17].
The Guidelines of the European Society of Anaesthesia regarding cirrhotic patients do not 
recommend routine preoperative correction of international normalized ratio (INR) (1.5–5) 
using fresh-frozen plasma but advise correction through point of care tests: rotational throm-
boelastometry or thromboelastography [18].
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3. Conduct of anaesthesia
Despite recent advances, liver transplantation remains a major challenge to the anaesthetist 
due to the important cardiovascular changes throughout surgery: important changes in pre-
load, afterload, arrhythmias, hypotension and hyperkalaemic events. All these increase the 
chances of severe cardiac dysfunction.
Liver transplantation is characterized by haemodynamic instability and various complica-
tions that can arise throughout the three important surgical phases: preanhepatic, anhepatic 
and neohepatic.
• Preanhepatic: dissection and liver mobilization takes place; usually massive bleeding can 
occur that can lead to hypovolaemia and haemorrhagic shock.
• Anhepatic: between clamping hepatic inflow and before graft reperfusion; consists of 
clamping of the inferior vena cava (IVC); significant decrease in cardiac output (CO) occurs.
• Neohepatic: characterized by liver reperfusion, reappearance of flow in the vena cava and 
vena porta, blood volume goes back to normal; can be complicated by reperfusion syn-
drome or bleeding from vascular anastomosis (hepatic artery, portal vein).
3.1. Patient monitoring during liver transplantation
Liver transplantation is performed under general anaesthesia, and the anaesthetic monitoring 
plays an important part in a successful liver transplantation as it can expose problems before 
irreversible damage occurs.
Haemodynamic instability is common during liver transplantation, and that is why the anaes-
thetic monitoring is complex, being divided into standard monitoring, haemodynamic (inva-
sive and non-invasive), neurologic and neuromuscular monitoring.
3.1.1. Standard monitoring
According to the American Society of Anaesthesia (ASA) protocols, standard monitoring 
applies to all patients during all types of anaesthesia with the aim of increasing patients’ 
quality of care. Trained personnel must be present in the operating room during the entire 
surgery, while continuous monitoring of the oxygenation, ventilation, circulation and tem-
perature is mandatory [19].
Oxygenation: gas monitoring as the level of inspired oxygen (FiO
2
) and the level of expired 
CO
2
 (ETCO
2
 capnography) and blood oxygenation in a continuous form as peripheral capil-
lary oxygen saturation (SpO
2
 pulsoxymetry).
Ventilation: chest movements and lung auscultation but also the volume of expired gas and 
capnography.
Circulation: continuous electrocardiogram (ECG) for rhythm, frequency, signs of ischaemia 
(ST segment), QT interval and measurement of blood pressure in a non-invasive way before 
induction of anaesthesia.
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Temperature: central temperature is the blood temperature which bathes the vital organs 
(heart and brain). Important sites of measurement are the following: tympanic membrane, 
nasopharynx, distal oesophagus, blood, urinary bladder and rectum [20].
3.1.2. Haemodynamic monitoring
Patients with chronic liver disease usually present many other systemic complications includ-
ing portal hypertension, ascites, coagulopathy, hyperdynamic circulatory syndrome (high 
cardiac index and low systemic vascular resistance) and cirrhotic cardiomyopathy. Due to 
all these changes, advanced haemodynamic monitoring is necessary. Monitoring parameters 
and normal values are shown in Table 1 [21].
3.1.2.1. Invasive blood pressure
Invasive arterial pressure monitoring represents standard practice during liver transplanta-
tion. The arterial catheter is usually inserted in the radial artery and is being used for continu-
ous pressure monitoring, blood gas analysis and other blood tests. Due to variations of radial 
artery pressure which may sometimes underestimate aortic pressure in hypotensive states, 
when high dose vasopressors are used and after reperfusion of the liver, some anaesthetists 
prefer using the femoral artery. Despite all these, the mean central and peripheral arterial 
pressures are usually the same [22]. An important problem when deciding the sites for cathe-
ter insertion is the cirrhotic coagulopathy which can lead to important puncture site bleeding. 
The number and sites of line insertion vary according to the transplant centre and experience.
3.1.2.2. Central venous pressure
Central venous pressure (CVP) monitoring is essential during liver transplantation. Central 
venous pressure is measured via a central catheter inserted in the superior vena cava system. 
Maintaining a low CVP in a normovolaemic patient can reduce the risk of bleeding but can 
increase the risk of vital organ hypoperfusion in case of a hypovolaemic patient or a massive 
bleeding [23].
3.1.2.3. Cardiac output and pulmonary artery pressures
Since its discovery, the pulmonary artery flotation catheter (Swan Ganz) has been considered 
the gold standard for cardiac output measurement. Swan Ganz catheters are still used rou-
tinely in some transplant centres around the world. A pulmonary artery catheter is manda-
tory if pulmonary hypertension is diagnosed or suspected.
Pulmonary artery pressures, cardiac output measurements and mixed venous oxygen satu-
ration help in the diagnosis and management of haemodynamic instability during surgery. 
The new modified Swan Ganz catheters help anaesthetists with continuous cardiac output 
measurements and right ventricular end-diastolic volume as a more accurate parameter of 
preload.
Despite the massive use in the last 40 years, its high cost and patient safety have led to ques-
tion its utility [24].
Anesthesia for Liver Transplantation
http://dx.doi.org/10.5772/intechopen.75167
215
Parameter Abbreviation Formula Normal value
Median arterial pressure MAP SBP+(2 × DBP)/3 75–105 mmHg
Arterial oxygen concentration CaO
2
(0.0138 × Hb × SaO
2
) + 0.003 × PaO
2
16–22 ml/dl
Venous oxygen concentration CvO
2
(0.0138 × Hb × SvO
2
) + 0.003 × PvO
2
15 ml/dl
Peripheral capillary oxygen 
saturation
SpO
2
Measurement 95–100%
Arteriovenous oxygen difference C(a-v)O
2
CaO
2
-CvO
2
4–6 ml/dl
Stroke volume SV CO/HR × 1000 60–100 ml/beat
Stroke volume index SVI CI/HR × 1000 33–47 ml/m2/beat
Cardiac output CO HR × SV/1000 4–8 l/min
Cardiac index CI CO/BSA 2.5–4 l/min/m2
Central venous pressure CVP Measurement 2–6 mmHg
Central venous oxygen saturation ScvO
2
Measurement 70–80%
Extravascular lung water EVLW CO × DSt-0.25GEDV
Extravascular lung water index EVLWI EVLW/PBW 0–7 ml/kgc
Global ejection fraction GEF SV × 4/GEDV >20%
Global end-diastolic volume GEDV CO × MTt × f(S1/S2)
Global end-diastolic volume index GEDI CI × MTt × f(S1/S2) 650–800 ml/kgc
Intrathoracic blood volume ITBV 1.25 × GEDV
Intrathoracic blood volume index ITBI 1.25 × GEDI 850–1000 ml/m2
Left ventricular stroke work LVSW SI × MAP×0.0144 8–10 g/m2/beat
Left ventricular stroke work index LVSWI SVI× (MAP-PAOP) × 0.0136 50–62 g/m2/beat
Mean pulmonary artery pressure MPAP PASP+(2 × PADP)/3 9–18 mmHg
Oxygen consumption VO
2
C(a-v)O
2
 × CO × 10 200–250 ml/min
Oxygen delivery DO
2
CaO
2
 × CO × 10 950–1150 ml/min
Pulmonary artery occlusion pressure PAOP Measurement 6–12 mmHg
Pulmonary artery systolic pressure PASP Measurement 15–30 mmHg
Pulmonary artery diastolic pressure PADP Measurement 8–15 mmHg
Pulmonary vascular resistance PVR 80× (MPAP-PAOP)/CO <250 dynes/s/cm5
Pulmonary vascular resistance index PVRI 80× (MPAP-PAOP)/CI 255–285 dynes/s/ 
cm5/m2
Stroke volume variation SVV SVmax-SVmin/SVmean×100 10–15%
Systemic vascular resistance SVR 80× (MAP-RAP)/CO 800–1200 dynes/s/
cm5
Systemic vascular resistance index SVRI 80× (MAP-RAP)/CI 1970–2390 dynes/
sec/cm5/m2
Table 1. Haemodynamic parameters.
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3.1.2.4. Other ways of measuring cardiac output
The pulse contour analysis is useful for continuous monitoring of cardiac output and needs 
frequent calibration via thermodilution technique:
• PiCCO system (Pulse-induced Contour Cardiac Output): this consists of a thermistor catheter 
placed in the femoral artery and can estimate stroke volume. A central venous catheter insert-
ed in the superior vena cava circulation is needed for the pulmonary calibration which must be 
done every 8 h in a haemodynamic stable patient and more frequent for unstable patients [25].
• LiDCO: it uses the same algorithm for stroke volume monitoring. Lithium chloride is used 
for transpulmonary calibration and can be injected into a peripheral vein.
• Transoesophageal echocardiography gives continuous information on ventricular function 
and volume status and allows immediate diagnosis of air or thrombus embolization. It 
also provides information regarding contractility, valvular function, pericardial or pleural 
effusion. Its main advantage is the ease of continuous use during surgery due to the anaes-
thetized and intubated patient [26].
• Thoracic bioimpedance: it estimates cardiac output and other haemodynamic parameters 
based on the electric properties of the thorax produced by blood movements during car-
diac cycle; rarely used in liver transplantation.
3.1.3. Neurologic monitoring
• Bispectral index: Fourier analysis of a fronto-parietal electroencephalogram (EEG). It varies 
between 0 (coma) and 10 (normal cortical activity) with an adequate value between 40 and 
60 in an anaesthetized patient [27].
• Transcranial Doppler echography can diagnose vasospasm, intracranial hypertension and 
cerebral death.
• Oxygen saturation in the jugular bulb (SjvO
2
): continuous monitoring of venous oxygen 
saturation via a central catheter inserted in the internal jugular vein that shows the balance 
between oxygen intake and consumption. Values below 50% show ischaemia while values 
above 75% show cerebral hyperaemia.
• Transcerebral cranial oximetry: resembles SjvO
2
.
• Electroencephalogram: rarely used for continuous monitoring during surgery; requires a 
trained anaesthetist who must differentiate pathological changes from normal changes in a 
cerebral activity during anaesthesia.
3.1.4. Neuromuscular monitoring
Residual neuromuscular block after the use of neuromuscular blockade agents can have a 
detrimental effect in patients after surgery causing inadequate hypoxic ventilatory response, 
depressed pharyngeal tonus leading to an increased risk of airway obstruction and death. 
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Peripheral nerve stimulation and depth of block can be assessed using single twitch, train of 
four, tetanic stimulation and double burst stimulation.
3.1.5. Other parameters monitored during liver transplantation
Other parameters monitored during liver transplantation include the following:
• hourly diuresis,
• haemoglobin and haematocrit,
• electrolytes,
• base excess and lactate,
• coagulation parameters via rotational thromboelastometry (ROTEM).
3.2. Haemodynamic management during the three phases of liver transplantation
3.2.1. Volemic resuscitation
Ever since the first successful liver transplantation in 1960, the surgery has been associated 
with significant bleeding and an increased amount of blood products transfused [28]. Blood 
products used during liver transplantation have declined significantly in the last 20 years. 
Even if bleeding risk has decreased over time, it still can induce a volemic stress.
Clamping of the inferior vena cava during the second phase (anhepatic) of the liver trans-
plantation leads to an important decrease in preload, CO and arterial pressure which need a 
quick diagnosis and management. Normal response of right ventricle (RV) and left ventricle 
(LV) to stress does not take place due to all the substances released from the liver in the 
anhepatic phase.
Continuous assessment of patient’s volemic status and the amount of perfused fluids repre-
sent the key to a successful liver transplantation. This can be done using dynamic measure-
ments of CVP and pulmonary capillary wedge pressure (PCWP), but these parameters do not 
correlate with changes in CO [29]. Another way of assessing fluid responsiveness is the use 
of stroke volume variation (SVV) and global end-diastolic volume index (GEDI). Inadequate 
fluid therapy can lead to pulmonary oedema, abnormal gas exchange, congestion, a decrease 
in perfusion and oedema of the graft [30].
This study does not offer an answer for the ideal monitoring system and guiding of fluid 
therapy [31]. In our clinic, the guidance of fluid management is done with the pulmonary 
thermodilution technique and pulse contour wave analysis via the PiCCO system.
Using adequate vasoactive substances, which protect the brain, heart and kidney, led to a 
greater haemodynamic stability, adequate CO and renal perfusion [31]. The CVP can also be 
correlated with the severity of the post-reperfusion syndrome [32].
Specific fluid management during liver transplantation can be described according to the 
three surgical phases:
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• Preanhepatic phase: cirrhotic patients usually have variate quantities of ascites; the anaes-
thetist must try and compensate it in order to reach normovolaemia and avoid hypovolae-
mia during the next phase (anhepatic) when clamping the inferior vena cava. Albumin of 
20 or 5% is used for volemic resuscitation.
• Anhepatic phase: fluid restriction is the best solution in this phase while maintaining ad-
equate arterial pressure with the help of vasopressors. The vasopressor of choice is nor-
adrenaline, and the parameters measured with the PiCCO system can guide us to using 
inotopes such as dobutamine.
• Neohepatic phase: in this stage, the patient needs adequate volemic resuscitation guided 
by the PiCCO parameters; an important decrease in vasopressors takes place.
Albumin determines the oncotic pressure that keeps fluids in the intravascular space. 
Cirrhotic patients usually have low albumin levels [32]. Studies have shown that the use of 
albumin during liver transplantation decreases the amount of intraoperative fluids used and 
the frequency of pulmonary oedema in cardiac and noncardiac surgery [33]. It has also been 
proved that albumin decreases mortality in cirrhotic patients, decreases the incidence of post-
reperfusion syndrome and the use of vasopressor agents [34].
The use of Hetastarch is not recommended as it affects platelet aggregability and increases 
the risk of bleeding by decreasing the concentration of coagulation factor 8 [33]. Gelatines can 
have numerous side effects: anaphylactic reactions, a decrease in thrombin generation and 
worsening of fibrinolysis which is specific in the anhepatic phase [35].
Manitol can be used in the anhepatic phase before clamping of the IVC (0.5 g/kgc) in order to 
avoid blood congestion in the liver and intraabdominal organ oedema [36].
PiCCO monitoring has a number of advantages: accurate CO calculations and guiding fluid 
management. ITBV is an accurate parameter of preload even when IVC is clamped [37]. We 
can also use SVV in order to predict fluid responsiveness [38].
Fluid management is done using PiCCO parameters determined during the three phases of the 
liver transplantation. This guidance of fluid therapy decreases the post-anaesthesia care unit 
stay and mortality [39]. The decisional tree regarding fluid management is presented in Table 2.
TOE can also be helpful in high-risk patients with various cardiac problems. It has the advan-
tage of direct assessment of cardiac contractility and assesses response to inotropes and vole-
mic status. It can diagnose embolic complications and cardiac tamponade [40].
The use of different monitoring techniques is the key to successful management of haemody-
namic instability and fluid guidance during liver transplantation.
3.2.2. Vasoactive substances and inotropes
There are a variety of substances that can be used when haemodynamic instability takes place 
during liver transplantation. Noradrenaline is most often used, followed by adrenaline and 
dobutamine. Indications are shown in Table 3.
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3.2.3. Postreperfusion syndrome
Liver reperfusion takes place in the neohepatic phase and is the most unstable period during 
liver transplantation, representing a real challenge for the anaesthetist. The postreperfusion 
syndrome is defined as a 30% decrease in the mean arterial pressure that lasts for at least a 
minute and appears in the first 5 min after the unclamping of the inferior vena cava (IVC) [41].
It can have severe consequences due to a decrease in cardiovascular function with haemody-
namic instability, abnormal acid base balance and metabolic abnormalities. Haemodynamic 
instability is the consequence of severe vasodilation, negative inotropic effects and massive 
bleeding which may appear during surgery. Graft reperfusion can have fatal consequences 
such as severe arrhythmias or asystole [42].
The incidence of PRS varies between 5.9 and 60% due to different surgical techniques, haemo-
dynamic intraoperative differences and geographic factors (in some countries, the number of 
reduced donors led to marginal graft use-expanded criteria donors) [43].
Causes of PRS are not yet clear, but there are several theories. Dyselectrolytemia, cold solu-
tions used for graft preservation and severe vasodilation due to NO release may contribute 
to PRS. Unclamping of the inferior vena cava leads to vasoactive pro-inflammatory substance 
released from Kupffer cells and which are the result of the postischaemic graft [44].
CI < 3 l/min/m2
GEDI <700 ml/m2 or ITBI <850 ml/m2 GEDI >700 ml/m2 or ITBI >850 ml/m2
ELWI <10 ELWI >10 ELWI <10 ELWI >10
Administer fluids Administer fluids (limited)
Vasopressor
Vasopressor Vasopressor
Fluid restriction
CI > 3 l/min/m2
GEDI <700 ml/m2 or ITBI <850 ml/m2 GEDI >700 ml/m2 or ITBI >850 ml/m2
ELWI <10 ml/m2 ELWI >10 ml/m2 ELWI <10 ml/m2 ELWI >10 ml/m2
Administer fluids Administer fluids No measure Fluid restriction
Table 2. Fluid therapy decisional tree.
Substance Indications Dose
Noradrenaline Arterial hypotension 0.2–1 μg/kgc/min
Adrenaline Asystole, severe arterial hypotension 0.01–0.5 μg/kgc/min
Dobutamine Cardiogenic shock 2.5–10 μg/kgc/min
Ephedrine Arterial hypotension
Before unclamping IVC
5–25 mg i.v. bolus every 10 min
Table 3. Main indications of inotropes during liver transplantation.
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One of the most important elements released from the graft is potassium as a result of the 
portal venous congestion. All these substances can contribute to postoperative ischaemia and 
reperfusion lesions [45]. Another theory is represented by the pro-inflammatory cytokines (IL 
1B, IL 2, IL 8, TNF-α) produced by ischaemia and released during the reperfusion of the graft 
leading to a marked inflammatory response and cellular death. They also have vasodilation 
and negative inotropic effect. The amount of pro-inflammatory cytokines released does not 
correlate with the duration of cold ischaemia time (CIT) [46].
Factors that may predict PRS are the following:
• donor-related: age, obesity, hypernatraemia (>155 mEq), hepatic steatosis, prolonged in-
tensive care unit (ICU),
• intraoperative factors: duration of the surgery,
• cold ischaemia time exceeding 6 h.
Risk factors include
• patient’s volemic status before reperfusion,
• myocardial depression (due to cold solutions released in circulation, abnormal acid base 
status),
• severity of metabolic acidosis.
Studies have shown that patients who had PRS have a higher risk of postoperative renal dys-
function and 15 days of mortality [43].
Postreperfusion syndrome leads to
• a decrease in arterial pressure and SVR,
• a decrease in CO,
• a moderate increase in PAP,
• frequent malignant arrhythmias.
Therapeutic options include the following:
• optimizing volemic status,
• adequate haemodynamic management,
• adequate graft perfusion; vasodilators are rarely used (calcium channel blockers, 
prostaglandins),
• liver graft wash with flush fluid of albumin 5% before IVC unclamping,
• correction of hypocalcaemia and hyperkalaemia,
• give ephedrine bolus 5 min before unclamping of the IVC in order to obtain a MAP of 
85–100 mmHg [47].
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3.3. Coagulation management
Cirrhotic patients have been regarded as having a high risk of bleeding due to standard coag-
ulation test abnormalities caused by cirrhotic coagulopathy. Recent studies have shown that 
bleeding episodes are caused by vascular abnormalities and portal hypertension [48].
Standard coagulation tests (prothrombin time, INR and activated partial thromboplastin 
time (aPTT)) reveal the deficit of procoagulant factors without showing the status of the 
anticoagulant factors.
In order to have an optimal view regarding cirrhotic coagulopathy, global coagulation tests 
(viscoelastic tests) are recommended [49].
Intraoperative blood transfusion has a negative impact on patient outcome. Intraoperative 
packed red cells and platelet transfusion are independent predictors of 1 year mortality 
[50].
There are a few measures that can decrease the need of blood transfusion:
• maintaining a low CVP,
• use of antifibrinolytic agents,
• use of recombinant activated factor 7,
• use of point of care tests for transfusion guidance.
The most important coagulation problems that can appear during the three transplant 
phases are specific for each phase:
• Preanhepatic phase: bleeding occurs due to extensive dissection, collateral circulation and 
portal hypertension. Maintaining a normal volemic status may lead to dilutional coagu-
lopathy and thrombocytopaenia [51]. A low CVP must be maintained in this phase. Cell 
saver can also be used after evacuation of ascites and before biliary anastomosis.
• Anhepatic phase: between clamping hepatic inflow and before graft reperfusion. Usually, 
minimal bleeding takes place here, but the risk exists. Platelets and coagulation factors are 
low due to loss and consumption from the previous phase. Synthesis and liver clearance do 
not exist. An increase in the release of tPA from endothelial cells and the absence of hepatic 
clearance can lead to hyperfibrinolysis and bleeding. Viscoelastic tests are mandatory for 
the diagnosis and management of hyperfibrinolysis.
• Neohepatic phase: bleeding can occur due to surgical problems or haemostatic abnormali-
ties. Usually, hypothermia, metabolic acidosis and hypocalcaemia must be corrected before 
any further decision is taken. Platelets are seized in the liver graft after reperfusion causing 
important thrombocytopaenia. Some platelets are partially activated in the liver graft and 
released in the circulation as inefficient.
Hyperfibrinolysis can often appear during liver transplantation, but is self-limited as long as 
the liver graft is viable.
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Antifibrinolytic agents can be used when diffuse bleeding occurs or when point of care 
tests show hyperfibrinolysis. In case of diffuse bleeding, the anaesthetist must correct hypo-
thermia, acidosis, hypocalcaemia, treat hyperfibrinolysis and then administer fibrinogen 
24 mg/kgc and platelets.
4. Conclusion
Anaesthesia for liver transplantation is one of the most difficult anaesthesias. This is due to 
the haemodynamic problems that can occur in the intraoperative, related both to the status of 
the patient (cardiomyopathy of the cirrhosis, etc.) and to the surgical moments (bleeding and 
reperfusion syndrome) as well as to the blood coagulation pattern of the patient.
A good understanding of the pathophysiology of the cirrhotic patient is very important for 
best decision making. Adequate perioperative management is extremely important for a suc-
cessful liver transplantation with a good outcome.
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